Grant McArthur
Lorenzo Galli Chair of Melanoma and Skin Cancers
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (22)
Year:
2026
Year:
2026
Year:
2025
Intracranial metastases (IM) are more common than primary malignant brain tumors, yet have been under-studied, presenting an important unmet clinical need. Many clinical trials excluded patients with IM, limiting our understanding of the intracranial efficacy of emerging treatments, though fortunately this is changing. Nevertheless, IM trials commonly exclude patients with leptomeningeal metastatic disease (LMD), related to their worse prognosis and/or expected lower likelihood of treatment-response. While criteria for assessing treatment-response for patients with confirmed LMD exist, there is a surprising lack of explicit guidelines regarding how LMD should be diagnosed or excluded in broader IM trials. This includes uncertainty regarding when cerebrospinal fluid (CSF) analysis is worthwhile, especially as this can be falsely negative, which is particularly relevant when MRI (magnetic resonance imaging) abnormalities are compelling. This lack of clear guidelines conveys a substantial risk of variability and misdiagnosis, with the potential to compromise trial results. Improved characterization also has the potential to demonstrate differences in treatment-response based on lesion morphology (especially parenchymal versus leptomeningeal). Here, we propose and illustrate new MRI criteria for classifying the range of IM appearances to minimize ambiguity in distinguishing between parenchymal IM and LMD, including recommended next steps. A diagnosis of LMD implies evidence of tumor cells within the CSF, hence we have divided MRI appearances into three groups based on the expected likelihood of this: 1) consistent with LMD and not requiring confirmation by CSF analysis; 2) equivocal, warranting correlation with CSF analysis and/or MRI spine; and 3) low suspicion of LMD, not requiring further testing. Importantly, we do not consider parenchymal metastases that contact a pial surface to be diagnostic of LMD; instead, we classify these within either the equivocal or low suspicion group, depending on morphology. Additionally, we outline potential diagnostic pitfalls and technical considerations for the MRI protocol.
Year:
2025
Year:
2025
Year:
2025
Background Resistance to BRAF and MEK inhibitors (BRAFi/MEKi) in metastatic melanoma frequently results in cross-resistance to immune checkpoint inhibitors (ICI), limiting effective treatment options. However, a subset of BRAFi/MEKi-resistant patients remains responsive to second-line ICI, suggesting heterogeneous underlying resistance mechanisms. This study aimed to explore the tumor immune microenvironment in BRAFi/MEKi-resistant melanoma to uncover factors influencing sensitivity to second-line ICI therapy. Method To investigate mechanisms underlying resistance and responsiveness to second-line ICIs, BRAFi/MEKi-resistant melanoma mouse models were used. Flow cytometry was employed to analyze immune cell populations within the tumor microenvironment, focusing on changes in CD8+T effector cells and other key immune subsets. RNA sequencing was performed to profile transcriptomic changes in resistant tumors, providing insights into the signaling pathways associated with resistance. Clinical samples from BRAFi/MEKi-resistant patients were further evaluated for correlations between immune profiles and key signaling pathways to support findings from the preclinical models. Results Using BRAFi/MEKi-resistant melanoma mouse models, we observed distinct alterations in the tumor-immune microenvironment. Tumors exhibiting resistance showed a significant increase in CD8+T effector cells following BRAFi/MEKi treatment, suggesting an immune-stimulatory response. Mechanistic analysis identified the activation of the EGFR-STAT signaling pathway as a key driver of intrinsic resistance in these models. Notably, these tumors retained sensitivity to second-line ICI therapy, contrasting with NRAS-driven BRAFi/MEKi-resistant tumors, which demonstrated cross-resistance to ICIs. Supporting these findings, clinical samples from BRAFi/MEKi-resistant patients revealed a correlation between elevated EGFR activation and higher immune scores, indicating potential sensitivity to ICI therapy in this subset of patients. Conclusion EGFR overexpression emerges as a potential predictive biomarker for responsiveness to second-line ICIs in BRAFi/MEKi-resistant melanoma. These findings underscore the need for stratified therapeutic approaches and highlight EGFR as a target for improving outcomes in ICI therapy.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (25)
Ilariya Tarasova
University of Melbourne
Emma Link
Peter MacCallum Cancer Institute
Sarah-Jane Dawson
Medical Oncologist and Group Leader
Peter MacCallum Cancer Institute
David Seignior
University of Melbourne
Anna Trigos
Group Leader
Peter MacCallum Cancer Institute
David Ritchie
Head of BMT
-
Claus Garbe
Professor of Dermatology
Eberhard Karls Universität Tübingen
Tamsin Robb
Research Associate
University of Cambridge
Penny E Lovat
Prof of Cellular Dermatology & Oncology
Newcastle University
Paul Ekert
Group Leader, Translational Tumour Biology
Children's Cancer Institute Australia
Hans Prenen
Antwerp University Hospital
Ben Tran
Peter MacCallum Cancer Institute
Timothy P. Stinear
University of Melbourne
Charlotta Windahl
Senior Lecturer
University of Auckland
Jayesh Desai
Associate Director, Clinical Research / Medical Oncology Lead and Trials Lead
-
Luc Thomas
enseignant-chercheur
Centre de Recherche en Cancérologie de Lyon
Fanny Franchini
Senior Research Fellow
University of Melbourne
Benjamin Solomon
Professor
University of Melbourne
Stefanie Thust
Clinical Associate Professor Neuroradiology
University of Nottingham
Paolo Antonio Ascierto
Full Professor
Università degli Studi di Napoli Federico II
Clare Scott
Walter and Eliza Hall Institute of Medical Research
Maarten IJzerman
Full professor
Erasmus University Rotterdam
Jolien Kessels
Vrije Universiteit Brussel
Ross Hannan
Australian National University
Bart Neyns
Diensthoofd
Vrije Universiteit Brussel
Make your next move.
Prepare your application
Review drafts before you send them.